IDVZ - ETF AI Analysis
Top Page
Opal International Dividend Income ETF (IDVZ)
IDVZ, the Opal International Dividend Income ETF, has a solid overall rating, supported by strong holdings like TSMC and AstraZeneca, which benefit from robust financial performance, positive earnings calls, and strategic growth in advanced technologies and healthcare. Other key positions such as GSK, TotalEnergies, and Reckitt Benckiser add to the fund’s quality through steady growth, attractive dividends, and supportive technical trends, while weaker names like British American Tobacco and Petrobras introduce some risk due to earnings volatility, revenue pressures, and bearish or uncertain momentum. The main risk factor is the fund’s exposure to specific sectors like energy and tobacco, where regulatory and profitability challenges can create added volatility.
IDVZ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 202.15M
- Region
- Global Ex-U.S.
- Expense Ratio
- 0.75%
- Beta
- 0.39
- Issuer
- Polen
- Inception Date
- Dec 26, 2024
- Dividend Yield
- 3.06%
- Asset Class
- Equity
- Index Tracked
- MSCI ACWI ex USA High Dividend Yield
IDVZ Summary
The Opal International Dividend Income ETF (IDVZ) tracks the MSCI ACWI ex USA High Dividend Yield index, focusing on companies outside the U.S. that pay relatively high dividends. It holds well-known international names like TSMC and ASML, along with firms in defensive areas such as consumer staples, health care, and utilities. Investors might consider IDVZ if they want regular income from dividends and broader global diversification beyond the U.S. stock market. A key risk is that international stocks and high-dividend companies can still fall in value, so the ETF’s price and income can go up and down with global markets.
How much will it cost me?
The Opal International Dividend Income ETF (IDVZ) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed to focus on high dividend yield opportunities across global markets, requiring more research and management effort.
What would affect this ETF?
The Opal International Dividend Income ETF (IDVZ) could benefit from global economic growth and increased demand for dividend-paying stocks, especially in sectors like Consumer Defensive and Financials, which make up a significant portion of its holdings. However, it may face challenges from rising interest rates, which can make dividend-focused investments less attractive, and potential regulatory changes or geopolitical tensions in its international markets. Its exposure to diverse sectors and regions helps mitigate risks but does not eliminate them entirely.
IDVZ Top 10 Holdings
IDVZ leans heavily on a mix of European banks, energy giants, and healthcare leaders to power its dividend story. Petrobras and TotalEnergies have been rising, giving the fund a strong tailwind from the energy patch, while TSMC adds a steady tech angle tied to global chip demand. On the flip side, consumer name Reckitt Benckiser and utility player Enel are losing steam, and Sanofi has been lagging, tempering overall momentum. With holdings spread across non-U.S. markets, the ETF offers global ex-U.S. income with a noticeable tilt toward financials, energy, and healthcare.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 PBR | Petroleo Brasileiro SA- Petrobras | 4.75% | $9.62M | $157.59B | 121.97% | 69Neutral |
 RBGLY | Reckitt Benckiser Group | 3.98% | $8.07M | $46.79B | -11.21% | 78Outperform |
 RHHBY | Roche Holding | 3.49% | $7.07M | $376.98B | 34.28% | 74Outperform |
 ENLAY | Enel SpA Unsponsored ADR | 3.46% | $7.01M | $102.42B | 3.88% | 71Outperform |
 IMBBY | Imperial Brands | 3.39% | $6.88M | $28.41B | -3.99% | 74Outperform |
 FR:TTE | TotalEnergies SE | 3.31% | $6.71M | EUR 178.44B | 53.66% | 78Outperform |
 GSK | GlaxoSmithKline | 3.14% | $6.36M | $100.19B | 13.84% | 77Outperform |
 BTI | British American Tobacco | 3.09% | $6.26M | $126.23B | 16.89% | 59Neutral |
 TSM | TSMC | 3.03% | $6.14M | $1.92T | 46.65% | 81Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
IDVZ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDVZ, the sentiment is Positive. The current price of 33.86 is above the 20-day moving average (MA) of 33.35, below the 50-day MA of 33.88, and above the 200-day MA of 33.78, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 55.77 is Neutral, neither overbought nor oversold. The STOCH value of 75.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDVZ.
IDVZ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IDVZ | $33.86 | $36.00(6.32% Upside) | $202.15M | 0.75% | 65Neutral |
 SCHY | $32.84 | $35.26(7.35% Upside) | $2.67B | 0.08% | 62Neutral |
 FDV | $33.56 | $36.71(9.37% Upside) | $969.36M | 0.50% | 72Outperform |
 FDD | $19.22 | $21.48(11.77% Upside) | $885.64M | 0.56% | 62Neutral |
 DWX | $46.72 | ― | $513.96M | 0.45% | 57Neutral |
 VDI | $35.50 | $40.17(13.13% Upside) | $15.89M | 0.39% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IDVZ | Opal International Dividend Income ETF | 33.86 | 4.09 | 13.75% | |
| SCHY | Schwab International Dividend Equity ETF | 32.84 | 5.37 | 19.53% | |
| FDV | Federated Hermes U.S. Strategic Dividend ETF | 33.56 | 5.67 | 20.35% | |
| FDD | First Trust Stoxx European Select Dividend Index Fund | 19.22 | 3.98 | 26.11% | |
| DWX | SPDR S&P International Dividend ETF | 46.72 | 5.14 | 12.36% | |
| VDI | Virtus International Dividend ETF | 35.50 | 6.00 | 20.33% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.